In adults presenting with acute chest pain, a normal (non‑ischemic) electrocardiogram, and two negative high‑sensitivity troponin results, when is cardiac computed tomography coronary angiography appropriate, and what are the required patient preparation steps and contraindications?

Targeted Use of CT Coronary Angiography in Acute Chest Pain

In adults with acute chest pain, normal ECG, and two negative high-sensitivity troponin results, coronary CT angiography (CCTA) is most appropriate for intermediate-risk patients (not low-risk patients), where it serves to exclude obstructive coronary artery disease and guide further management.

Risk Stratification Determines CCTA Appropriateness

The critical first step is determining whether the patient is low-risk or intermediate-risk after ruling out myocardial infarction:

Low-Risk Patients (<1% 30-day MACE risk)

• Do NOT routinely perform CCTA before discharge 1
• These patients should be discharged home without urgent cardiac testing 2
• Arrange outpatient follow-up within 1-2 weeks 1
• If no follow-up is available, only then consider further testing before discharge 1

This represents a critical pitfall: the 2021 AHA/ACC guidelines explicitly state that further diagnostic testing (including CCTA, stress testing, or myocardial perfusion imaging) should NOT be routinely used in low-risk patients after MI has been ruled out 1. The most recent 2026 TARGET-CTCA trial reinforces this, showing that routine CCTA in patients with ruled-out MI did not reduce subsequent cardiac events 3.

Intermediate-Risk Patients

CCTA is Class I recommendation (Level of Evidence: A) for intermediate-risk patients with no known CAD 2. This is where CCTA provides maximum clinical utility for:

• Exclusion of atherosclerotic plaque and obstructive CAD
• Shortening length of stay
• Reducing costs compared to inpatient admission 2

Patient Preparation Requirements

Pre-scan Assessment

• Heart rate control is essential: Target heart rate <65 bpm for optimal image quality
• Administer beta-blockers (oral or IV) if heart rate elevated and no contraindications 4, 5
• Assess renal function: Calculate eGFR before contrast administration 4, 5
• Verify patient can hold breath: Single breath-hold of 5-10 seconds required 5

Immediate Pre-scan Steps

• Sublingual nitroglycerin (0.4-0.8 mg) administered 3-5 minutes before scan to dilate coronary arteries (unless contraindicated) 5
• Patient positioned supine with arms above head
• ECG leads properly placed for gating

Absolute Contraindications

Do not perform CCTA if:

• Severe renal impairment (eGFR <30 mL/min/1.73m²) without dialysis access 4, 5
• Known severe contrast allergy without adequate premedication 4, 5
• Pregnancy (radiation exposure) 5
• Inability to cooperate (cannot hold breath, severe anxiety, altered mental status) 5
• Hemodynamic instability requiring immediate intervention 4

Relative Contraindications Requiring Consideration

• Atrial fibrillation or irregular rhythm: Significantly degrades image quality, though newer scanners with wider detector coverage may still allow diagnostic imaging 5
• Severe obesity: May exceed scanner table weight limit or result in excessive image noise 5
• Extensive coronary calcification on calcium scoring: Agatston score >400 reduces diagnostic accuracy 5
• Tachycardia >65 bpm despite beta-blockade: Consider alternative testing 5

Clinical Algorithm for CCTA Use

After ruling out MI with normal ECG and two negative hs-troponins:

1. Calculate risk score (HEART, TIMI, or GRACE) 2, 1

2. If LOW-RISK (<1% 30-day MACE):

   • Discharge home
   • Arrange 1-2 week outpatient follow-up
   • NO routine CCTA before discharge

3. If INTERMEDIATE-RISK:

   • Check contraindications (renal function, contrast allergy, pregnancy)
   • Assess heart rate and administer beta-blocker if needed
   • Perform CCTA within 24 hours (target <24h per recent consensus) 4
   • If CCTA unavailable, transfer to facility with capability or perform stress imaging within 7 days 4

4. CCTA Results Guide Management:

   • No CAD or non-obstructive CAD (<50% stenosis): Discharge with medical therapy optimization 2
   • Stenosis 40-90%: Consider FFR-CT for vessel-specific ischemia assessment 2
   • Obstructive CAD (≥50% stenosis): Proceed to stress testing or invasive angiography based on clinical context 2
   • Inconclusive CCTA: Perform stress imaging (echo, SPECT, PET, or CMR) 2

Special Considerations in the High-Sensitivity Troponin Era

The widespread adoption of hs-troponin has increased false positives ("troponinosis"), making CCTA particularly valuable for patients with inconclusively elevated troponins 4, 6. In this subset, CCTA achieved 98% negative predictive value for type 1 NSTE-ACS 6, helping prevent unnecessary catheterizations while identifying alternative diagnoses (myocarditis, stress cardiomyopathy, non-cardiac causes).

Key Pitfalls to Avoid

• Over-testing low-risk patients: The most common error is ordering CCTA in patients who meet low-risk criteria and should simply be discharged 1
• Ignoring heart rate: Proceeding with CCTA when heart rate >65 bpm without beta-blockade results in non-diagnostic studies 5
• Missing renal dysfunction: Always check eGFR before contrast administration 4
• Assuming CCTA replaces clinical judgment: Recent evidence shows no mortality benefit from routine CCTA in ruled-out MI patients 3, emphasizing appropriate patient selection

The evidence strongly supports CCTA for intermediate-risk patients with no known CAD, where it provides Class I Level A evidence for excluding obstructive disease 2, but explicitly recommends against routine use in low-risk patients after MI exclusion 1.